Status:
COMPLETED
An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Spinal Muscular Atrophy
Eligibility:
All Genders
28-182 years
Phase:
PHASE1
PHASE2
Brief Summary
An open-label, multi-part, first-in-human study of oral branaplam in infants with Type 1 spinal muscular atrophy. The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (...
Detailed Description
This was an open-label, multi-part, first-in-human, proof of concept study in infants with Type 1 spinal muscular atrophy who have exactly 2 copies of SMN2, to evaluate safety, tolerability, PK, PD an...
Eligibility Criteria
Inclusion
- Common for both Parts 1 and 2:
- Type 1 SMA, diagnosed clinically, with symptom onset \<6 months of age and genetic confirmation of mutations in both alleles of the SMN1 gene, and with SMN2 copy number of 2.
- Best supportive care in place and stable for at least 14 days before screening.
- Must be able to demonstrate antigravity strength in both biceps. At birth gestational age \>32 weeks and body weight at birth \>2 kg.
- Must live within 2 hours drive of study center. Clearance should be obtained from the site investigator and sponsor if the patient resides more than 2 hours ground travel from the study center
- Specific for Part 1
- Age at screening between 1 and 7 months
- Must have or agree to have placement of feeding tube for enteral access via nasogastric (NG), nasojejunal (NJ), percutaneous gastrostomy (PEG), or percutaneous jejunostomy (PEJ) tube for administration of branaplam (for patients in whom branaplam cannot be administered orally ; NG tube may be removed between doses).
- Specific for Part 2
- Age at screening between 30 and 180 days of age
- Must have or agree to have placement of feeding tube for enteral access via nasogastric (NG), nasojejunal (NJ), percutaneous gastrostomy (PEG), or percutaneous jejunostomy (PEJ) tube for administration of branaplam (for the first administration only and for patients in whom branaplam cannot be administered orally; NG tube may be removed between doses).
- Minimum CHOP INTEND score of 15 at baseline
- Must be able to feed orally for all nutritional needs and be greater than the 2nd percentile for weight on the standard growth curves for the country of origin
Exclusion
- Common for both Parts 1 and 2:
- Neurologic, or neuromuscular conditions other than SMA.
- Anemia, leukopenia, neutropenia or thrombocytopenia
- Hepatic dysfunction
- Age adjusted renal dysfunction
- Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the screening period.
- Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the screening period.
- Excluding SMA, any medically unstable condition including cardiomyopathy, hepatic dysfunction, kidney disorder, endocrine disorder, GI disorders, prematurity of \<32 weeks gestation, metabolic disorders, severe respiratory compromise and significant brain abnormalities or injuries including hypoxic-ischemic encephalopathy.
- Current diagnosis of cardiac and/or vascular abnormalities or ECG abnormalities
- Acute or ongoing medical condition that, according to the Site Investigator and discussed with sponsor, would interfere with the conduct and assessments of the study. Examples are medical disability other than SMA that would interfere with the assessment of safety or would compromise the ability of the subject to undergo study procedures including be assessed by CHOP INTEND motor scale, changes in hematologic parameters or gastrointestinal dysfunction that would compromise the ability of adequate assessment of safety
- Specific for Part 1
- Use of other investigational drugs within 14 days.
- Intractable seizure disorder (other than inactive febrile seizures).
- Persistent (in the opinion of the Investigator) hypoxemia (O2 saturation awake \<92% or O2 saturation asleep \<91%, without ventilation support) or requiring oral suctioning \>2 per day, or presence of a tracheostomy.
- Specific for Part 2
- Use of nusinersen or gene transfer at any time or other investigational drugs within 14 days.
- Intractable epilepsy
- Persistent (in the opinion of the Investigator) hypoxemia (O2 saturation awake \<92% or O2 saturation asleep \<91%, without ventilation support), or presence of a tracheostomy.
Key Trial Info
Start Date :
April 2 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 29 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT02268552
Start Date
April 2 2015
End Date
December 29 2022
Last Update
April 9 2025
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Ghent, Belgium, 9000
2
Novartis Investigative Site
Leuven, Belgium, 3000
3
Novartis Investigative Site
Sofia, Bulgaria, 1606
4
Novartis Investigative Site
Copenhagen, Denmark, 2100 O